Open Access · CC BY-NC-ND 4.0
From MTD to OBD: evolution, integration, and challenges in dose-finding methods for phase I oncology trials
Letters in Drug Design & Discovery · 2026-10 · 100644
DOI: 10.1016/j.lddd.2026.100644 ↗Kurz gefasst
Fachartikel in der Zeitschrift Letters in Drug Design & Discovery, 2026-10. Verfasst von Yi Luo und 2 weiteren Autor:innen. Die Arbeit nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Luo, Y., Shu, Q., & Tian, L. (2026). From MTD to OBD: evolution, integration, and challenges in dose-finding methods for phase I oncology trials. Letters in Drug Design & Discovery, 100644. https://doi.org/10.1016/j.lddd.2026.100644
Vancouver
Luo Y, Shu Q, Tian L. From MTD to OBD: evolution, integration, and challenges in dose-finding methods for phase I oncology trials. Letters in Drug Design & Discovery. 2026:100644. doi:10.1016/j.lddd.2026.100644
BibTeX
@article{Luo2026,
author = {Luo, Yi and Shu, Qun and Tian, Longben},
title = {From MTD to OBD: evolution, integration, and challenges in dose-finding methods for phase I oncology trials},
journal = {Letters in Drug Design & Discovery},
year = {2026},
pages = {100644},
doi = {10.1016/j.lddd.2026.100644}
}
EUVIMED